ArticleAntioxidants (Basel, Switzerland)2025
Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Chlorogenic Acid Alleviates Experimental Asthma by Reprogramming DHA Metabolism to Inhibit Ferroptosis.International journal of molecular sciences · 2026Article
- StudyingPharmaceuticals (Basel, Switzerland) · 2025Review
- Cuspidatyl Ferulate, a Novel Phenolic Acid fromAntioxidants (Basel, Switzerland) · 2025Article
- Special Issue "Natural Products in Drug Discovery and Development".International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
background and purposeVulvovaginal candidiasis (VVC), caused by
methodsGC-MS identified SXC's major bioactive components, while broth microdilution assays determined minimum inhibitory concentrations (MICs) against bacterial/fungal pathogens, and synergistic interactions with amphotericin B (AmB) or fluconazole (FLC) were assessed via time-kill kinetics. Anti-biofilm activity was quantified using crystal violet/XTT assays, and in vitro studies evaluated SXC's effects on
resultsGas chromatography-mass spectrometry identified 10 key volatile components contributing to SXC's activity. SXC exhibited broad-spectrum antimicrobial activity with MIC values ranging from 0.125-16 μL/mL against bacterial and fungal pathogens, including fluconazole-resistant Candida strains. Time-kill assays revealed that combinations of AmB-SXC and FLC-SXC achieved sustained synergistic bactericidal activity across all tested strains. Mechanistic studies revealed SXC's dual antifungal actions: inhibition of
conclusionsSXC shows promise as a broad-spectrum natural antimicrobial against fungal pathogens. It inhibited
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.